Exelixis and Sairopa enter development and option agreement for anti-SIRPα antibody ADU-1805

Nov. 3, 2022

Exelixis Inc. and Sairopa BV have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα.

BioWorld Science Collaboration Cancer Immuno-oncology Monoclonal antibody

Today's news in brief

BioWorld

BioWorld briefs for July 3, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 3, 2025.

AI-generated illustration of CAR T cells

Researchers arm CAR T cells to fight solid tumors

BioWorld

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...

Bioversys, Shionogi in CHF529M lung infection collaboration

BioWorld Science

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...

Medtronic receives CE mark for its Vitalflow ECMO system

BioWorld MedTech

Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...